Answers are grounded in this paper and cite their sources.
Total synthesis of orbiculamide A demonstrates effective bromodesilylation in peptide compounds, highlighting new pathways for drug development.
Orbiculamide A, a macrocyclic peptide with antimitotic and antileukemic properties, contains several synthetically challenging structural motifs, including a 2-bromo-5-hydroxytryptophan residue, that presents a widely recognized synthetic challenge. Here, we report the first total synthesis of orbiculamide A, where central to our approach is a chemoselective, late-stage bromodesilylation strategy. This work provides a foundation for the synthesis of related natural products and scaffold diversification of medicinal peptides.
No takes yet. Share an insight, caveat, or question.
Newell et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: